Kura Oncology Reports $15.3 Million Collaboration Revenue and $66.1 Million Net Loss in Q2 2025

Kura Oncology, Inc. reported its financial results for the second quarter of 2025, revealing a collaboration revenue of $15.3 million, a significant increase from zero revenue in the same period last year. For the first half of 2025, total revenue reached $29.4 million, attributed to services performed under the Kyowa License Agreement. Despite this revenue growth, the company reported a net loss of $66.1 million for the quarter, compared to a loss of $50.8 million in the prior year, reflecting an increase in operating expenses driven by heightened research and development activities.

Total operating expenses for the second quarter of 2025 amounted to $88.0 million, up from $56.4 million in the same quarter of 2024. The increase was primarily due to a rise in research and development costs, which reached $62.8 million, compared to $39.7 million in the previous year. This increase was largely driven by expenses related to the ongoing clinical trials for Kura's lead product candidate, ziftomenib, as well as costs associated with the development of other candidates like KO-2806 and tipifarnib. General and administrative expenses also rose to $25.2 million from $16.7 million, reflecting increased pre-commercial planning and personnel costs.

Kura's balance sheet as of June 30, 2025, showed total assets of $682.4 million, down from $760.2 million at the end of 2024. The decrease was primarily due to a reduction in cash and cash equivalents, which fell to $81.9 million from $224.5 million. The company's total liabilities increased to $376.9 million, up from $346.5 million, largely due to an increase in current liabilities, including contract liabilities that rose to $49.4 million from $24.3 million. Stockholders' equity also declined to $305.5 million from $413.6 million, primarily due to the accumulated deficit growing to $1.0 billion.

Strategically, Kura has made significant advancements in its clinical pipeline, particularly with ziftomenib, which is being developed for the treatment of acute myeloid leukemia (AML). The company has initiated multiple clinical trials, including the KOMET-001 and KOMET-007 trials, and has received Breakthrough Therapy Designation from the FDA for ziftomenib. Additionally, Kura entered into a co-promotion agreement with Kyowa Kirin to enhance the commercialization efforts for ziftomenib in the U.S. market.

Looking ahead, Kura anticipates that its cash, cash equivalents, and short-term investments will be sufficient to fund operations into 2027, supported by collaboration funding under the Kyowa License Agreement. However, the company acknowledges the need for substantial additional financing to continue its research and development activities and to support potential commercialization efforts. Kura's management remains focused on advancing its clinical programs while navigating the financial challenges typical of a clinical-stage biopharmaceutical company.